Notably, FYN itself is a druggable target [39], and exposure of synovial sarcoma cells to the small molecule PP2 (a potent FYN inhibitor) brings about the enhanced efficacy of HDAC inhibitor treatment. This evidence concerns the gene FYN and synovial sarcoma.